Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

Browse trials for

• Wolman Disease 35

Keywords

• LIPA
• Wolman Disease
• Wolman Phenotype
• Acid Lipase Deficiency
• Acid Cholesteryl Hydrolase
• Acid Lipase Disease Deficiency, type 2
• Cholesteryl Ester Storage Disease (CESD)
• Cholesteryl Ester Hydrolase Deficiency
• Early Onset Lysosomal Acid Lipase Deficiency (Wolman Disease)
• LAL Deficiency
• Late Onset Lysosomal Acid Lipase Deficiency (CESD)
• Wolman Disease (early onset LAL Deficiency)
• Related Disorders:
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Non-alcoholic Steatohepatitis (NASH)
• Alcoholic Liver Disease
• Cryptogenic Cirrhosis
• Niemann-Pick Disease (NPD) Type C
• Chanarin Dorfman Syndrome

Wolman Disease

35 studies on the registry are indexed under Wolman Disease; 5 are open to participants now.

This study's enrollment of 10 is below the median of 31 across 14 interventional studies indexed under Wolman Disease.

Lead sponsor

Alexion Pharmaceuticals, Inc. is the lead sponsor of 249 studies on the registry; 25 are open to participants now.

Of its 98 completed or terminated interventional studies of FDA-regulated products, 70 (71%) have results posted.

Study arms

• Experimental
  Open-Label Sebelipase Alfa

  All participants initiated once weekly (qw) intravenous (IV) infusions with sebelipase alfa at a dose of 1 milligram/kilogram (mg/kg) qw. A participant who met protocol defined dose escalation criteria at a dose of 1 mg/kg qw could be considered for a dose escalation to 3 mg/kg qw. If a participant continued to meet dose escalation criteria after at least 4 infusions at a dose of 3 mg/kg qw, the participant could be considered for a further dose escalation to 5 mg/kg qw. Under country-specific provisions (United Kingdom only), participants could be considered for a further dose escalation to 7.5 mg/kg qw if a thorough case review indicated that a participant continued to have evidence of disease progression at a dose of 5 mg/kg qw. All dose escalations were contingent upon acceptable safety and tolerability of preceding infusions and were undertaken by mutual agreement of the Investigator and Sponsor and after approval by an independent safety committee.

  Drug: Sebelipase Alfa

Interventions

• DrugSebelipase Alfa

  Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.

  Also known as: SBC-102

Primary outcomes

1. Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)

   The number of participants experiencing severe TEAEs is presented for participants who received sebelipase alfa in this open-label study. Adverse events were obtained through spontaneous reporting or elicited by specific questioning or examination of the participant's parent or legal guardian. An adverse event was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant, whether or not causally related to administration of study drug. Adverse event severity was graded by the Investigator as mild, moderate, or severe based on definitions developed from Clinical Data Interchange Standards Consortium Study Data Tabulation Model standard terminology v3.1.1. Adverse events reporting was from the date of informed consent until completion of the follow-up visit at approximately 30 days after the last dose of study drug. A summary of all serious and other nonserious AEs regardless of causality is located in the Reported AE module.

   Time frame: Screening through Month 37

Secondary outcomes

1. Percentage Of Participants Surviving To 12, 18, 24, And 36 Months Of Age

   The percentage of participants in the FAS who survived to 12, 18, 24, and 36 months of age. The exact confidence interval was calculated using the Clopper-Pearson method. Participants with unknown survival status at the age specified in the analysis were excluded. At 36 months, there were 2 participants who were alive and still on study who had not yet reached the age specified in the analysis. As such, these participants were excluded from the calculation of percent surviving.

   Time frame: Baseline through Month 12, Month 18, Month 24, and Month 36

2. Median Age At Death

   Age at death for participants who died during the study. All deaths were assessed by the Investigator as unrelated to study drug.

   Time frame: Baseline through Month 36

3. Change From Baseline In Percentiles For Weight For Age (WFA) At 12, 24, And 36 Months

   This outcome measure evaluated the effects of sebelipase alfa on growth by measuring the changes from baseline in percentiles for WFA. Percentiles for WFA were summarized as observed values by visit. Baseline was defined as the last available assessment prior to the first infusion of sebelipase alfa.

   Time frame: Baseline, Month 12, Month 24, and Month 36

4. Number Of Participants With Stunting, Wasting, Or Underweight At Baseline, 12, 24, And 36 Months

   The number of participants who met criteria for the following 3 dichotomous indicators of under nutrition were reported. These indicators included the following: 1. Stunting was defined as at least 2 standard deviations below the median for length-for-age/height-for-age. 2. Wasting was defined as wasting at least 2 standard deviations below the median for weight-for-length/weight-for-height. 3. Underweight was defined as at least 2 standard deviations below the median for WFA.

   Time frame: Baseline to Month 12, Month 24, and Month 36

5. Change From Baseline In Serum Transaminases (ALT And AST) At Month 12, 24, And 36

   This outcome measure evaluated the effects of sebelipase alfa on liver function by measuring the change from baseline in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at months 12, 24, and 36. Results are reported in units/liter (U/L).

   Time frame: Baseline, Month 12, Month 24, and Month 36

6. Change From Baseline In Serum Ferritin At Month 12, 24, And 36

   The median change in the inflammatory marker serum ferritin from Baseline to Months 12, 24, and 36 is presented. The number of participants analyzed reflects only those from the FAS who had both a baseline value and a value at the indicated timepoint (Months 12, 24, and 36). Results are reported in micrograms (ug)/L.

   Time frame: Baseline, Month 12, Month 24, and Month 36

7. Number Of Participants Achieving And Maintaining Transfusion-free Hemoglobin Normalization (TFHN)

   The number of participants achieving and maintaining TFHN are presented. For TFHN to be achieved, the participant had to meet the following criteria: 1. Two post baseline measurements of hemoglobin, at least 4 weeks apart, were above the age-adjusted lower limit of normal (LLN); 2. No known additional measurements of hemoglobin were below the age-adjusted LLN during the (minimum) 4 week period; 3. No transfusions were administered to the participant during the (minimum) 4 week period, or for 2 weeks prior to the first hemoglobin measurement in the (minimum) 4 week period. If all 3 criteria were met, a participant was considered to have achieved TFHN on the date of the first hemoglobin assessment in the 4 week period. A participant was considered to have maintained TFHN if he/she was transfusion free at Week 6 and had no abnormally low hemoglobin levels (levels below the age adjusted LLN) beginning at Week 8 of the study and continuing for at least 13 weeks (3 months).

   Time frame: Baseline through Month 36

Baseline characteristics

Publications

• Balwani M, Breen C, Enns GM, Deegan PB, Honzik T, Jones S, Kane JP, Malinova V, Sharma R, Stock EO, Valayannopoulos V, Wraith JE, Burg J, Eckert S, Schneider E, Quinn AG. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology. 2013 Sep;58(3):950-7. doi: 10.1002/hep.26289. Epub 2013 Mar 28. PubMed 23348766 ↗
• Jones SA, Valayannopoulos V, Schneider E, Eckert S, Banikazemi M, Bialer M, Cederbaum S, Chan A, Dhawan A, Di Rocco M, Domm J, Enns GM, Finegold D, Gargus JJ, Guardamagna O, Hendriksz C, Mahmoud IG, Raiman J, Selim LA, Whitley CB, Zaki O, Quinn AG. Rapid progression and mortality of lysosomal acid lipase deficiency presenting in infants. Genet Med. 2016 May;18(5):452-8. doi: 10.1038/gim.2015.108. Epub 2015 Aug 27. PubMed 26312827 ↗
• Jones SA, Rojas-Caro S, Quinn AG, Friedman M, Marulkar S, Ezgu F, Zaki O, Gargus JJ, Hughes J, Plantaz D, Vara R, Eckert S, Arnoux JB, Brassier A, Le Quan Sang KH, Valayannopoulos V. Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study. Orphanet J Rare Dis. 2017 Feb 8;12(1):25. doi: 10.1186/s13023-017-0587-3. PubMed 28179030 ↗

Study documents

• Study protocol · Dec 8, 2015
• Statistical analysis plan · Jul 31, 2018

Documents are hosted by the registry — open the source record to download them.